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Vascular Endothelial Growth Factor and Ischemic Heart Disease Risk:
A Mendelian Randomization Study
Shiu Lun Au Yeung, MPH, PhD; Hugh Simon Hung San Lam, MBBChir; C. Mary Schooling, PhD
Background-—Vascular endothelial growth factor (VEGF) has angiogenic and possibly proatherosclerotic properties. Observation-
ally it is positively associated with cardiovascular disease, although these observations could be confounded or due to reverse
causation. We assessed ischemic heart disease (IHD) risk by genetically predicted VEGF, ie, using Mendelian randomization.
Methods and Results-—Single nucleotide polymorphisms (SNPs) predicting VEGF level, at genome-wide signiﬁcance, were applied
to the CARDIoGRAMplusC4D 1000 Genomes-based genome-wide association study IHD case (n=60 801)-control (n=123 504)
study. We obtained unconfounded estimates using instrumental variable analysis by combining the Wald estimates for each SNP
using inverse variance weighting and Mendelian randomization–Egger regression. Based on 9 SNPs independently predicting VEGF
(rs1740073 [C6orf223], rs2375981 [KCNV2], rs2639990 [ZADH2], rs4782371 [ZFPM1], rs6921438 [LOC100132354], rs7043199
[VLDLR-AS1], rs10761741 [JMJD1C], rs6993770 [ZFPM2], and rs114694170 [MEF2C]), VEGF was unrelated to IHD (odds ratio
0.99 per log-transformed pg/mL, 95%CI 0.96-1.02) using inverse variance weighting. However, Mendelian randomization–Egger
regression suggested an inverse relation of VEGF with IHD (odds ratio 0.95, 95%CI 0.91-0.99), although the association was not
evident after excluding the lead SNP (rs6921438) or additionally excluding the pleiotropic SNP (rs6993770).
Conclusions-—Our study does not provide strong evidence for a positive effect of VEGF on IHD but does not rule out the possibility
that some speciﬁc types of VEGF, for which genetic predictors have not yet been identiﬁed, might play a role. ( J Am Heart Assoc.
2017;6:e005619. DOI: 10.1161/JAHA.117.005619.)
Key Words: ischemic heart disease • Mendelian randomization • vascular endothelial growth factor
V ascular endothelial growth factor (VEGF) is thought tohave angiogenic and proatherosclerotic properties.1,2
Observationally VEGF is positively associated with cardiovas-
cular disease (CVD), although the association may not be
linear.3 However, it is unclear whether the association is due
to confounding or reverse causation because VEGF may be a
symptom of acute myocardial infarction.4 VEGF is
pharmacologically modiﬁable,5 so assessment of its potential
as a target of intervention for CVD prevention is important,
and clarifying its etiological role may improve understanding
of CVD. Trials have shown that statins lower VEGF,5 raising
the possibility that one of the additional beneﬁts of statins
may be due to effects on VEGF. Little evidence from
randomized controlled trials concerning the effects of VEGF
on CVD in the general population is available. Previous
randomized controlled trials among patients with ischemic
disease did not provide strong evidence for clinical efﬁcacy of
VEGF.6
Mendelian randomization studies use genetic predictors
randomly allocated during conception, analogous to the
randomization process in a randomized controlled trial.
Genetic variants are unlikely to be affected by factors such
as lifestyle or socioeconomic position, which commonly
confound observational studies. Furthermore, genetic variants
are unlikely to be affected by disease outcomes, and hence,
Mendelian randomization is more resistant to reverse causa-
tion.7 As a result, this design may provide more credible
evidence concerning the role of VEGF in CVD than observa-
tional studies.8 Mendelian randomization studies may also
provide evidence more relevant to effects in the general
population because randomized controlled trials are often
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conducted in patient populations only.6 Meta-analysis of
candidate gene studies examining the relation of VEGF-related
genetic polymorphisms to coronary artery disease found no
evidence supporting a causal effect of VEGF on ischemic heart
disease (IHD), but these studies were of limited size (630
participants in the analysis for IHD)9 and so were potentially
underpowered as well as open to publication bias. To provide
a more deﬁnitive answer about the role of VEGF in CVD, both
as a target of intervention and from an etiological perspective,
we conducted a Mendelian randomization study using the
largest genome-wide association study (GWAS) to date of
VEGF (n=16 112),10 applied to a large IHD case (n=60 801
for IHD)-control (n=123 504) study.11
Methods
Study Design
This is a Mendelian randomization study, ie, an instrumental
variable analysis with a genetic instrument, and has 3 key
assumptions: (1) the genetic instrument predicts the exposure;
(2) the genetic instrument is not associated with confounders
of the exposure-outcome relation; and (3) the genetic instru-
ment does not affect the outcome other than via its inﬂuence
on the exposure of interest (exclusion restriction, ie, absence of
horizontal pleiotropy). We attempted to address these assump-
tions ﬁrst by choosing as genetic instruments for VEGF genetic
variants that strongly predicted VEGF, second by using genetic
instruments because genetic instruments are unlikely to be
associated with confounders of the exposure-outcome relation,
and third by checking whether the genetic variants predicting
VEGF are known to have any horizontal pleiotropic effects on
IHD, ie, effects on IHD via pathways that do not involve VEGF. In
the context of Mendelian randomization, if an instrument’s
pleiotropic effect is mediated via VEGF (ie, vertical pleiotropy),
then it would not violate the instrumental variable
assumption.12 Furthermore, there are also other assumptions
such as negligible measurement error for the gene-exposure
relation (no measurement error assumption), if the variance of
the estimates does not take into account the variance of the
genetic variants on exposure, which is likely to be satisﬁed in
large samples.13
Genetically Predicted VEGF
From a GWAS of VEGF, based on 16 112 adults of European
ancestry with a mean age of 54.8 years using the 1000
Genomes reference data, single nucleotide polymorphisms
(SNPs) that predicted VEGF (per log-transformed pg/mL) at
genome-wide signiﬁcance (P<59108) were obtained.10 Cor-
relations among these SNPs were evaluated from the r2 for
linkage disequilibrium obtained from SNP Annotation and
Proxy Search (http://www.broad.mit.edu/mpg/snap/ldsearc
hpw.php) using 1000 Genomes (pilot 1, CEU) reference data.
To rule out the possibility of violation of the exclusion
restriction assumption by pleiotropic SNPs that affect IHD
through exposures other than VEGF, we also cross-checked
any other phenotypes these SNPs were associated with via a
comprehensive genotype-to-phenotype cross-reference,
Ensembl (Release 87) (http://www.ensembl.org/index.html).
Ensembl gives any known traits associated with SNPs
reported in another database such as the NHGRI-EBI GWAS
catalog, which curates SNP-phenotype relations from pub-
lished genome-wide association studies, usually using the
conventional threshold for genome-wide signiﬁcance of
59108. Here, traits known to cause IHD (eg, lipids, blood
pressure) were considered as horizontal pleiotropic effects
and violated the exclusion restriction assumption. However,
we cannot rule out the possibility that such traits indicate
vertical pleiotropy (ie, the genetic instrument has multiple
traits that are all mediated via VEGF), which does not
invalidate the exclusion-restriction assumption,12 or that the
selected SNPs may have unmeasured/unexpected pleiotropic
effects that can invalidate the inverse variance weighting
analysis. We also conducted Mendelian randomization (MR)-
Egger regression to reduce the risk of biases due to
potentially inappropriate inclusion/exclusion of SNPs.
Genetic Predictors of Ischemic Heart Disease
Data on coronary artery disease and myocardial infarction have
been contributed by CARDIoGRAMPLUSC4D investigators and
have been downloaded from www.CARDIOGRAMPLUSC4-
D.ORG.11 CARDIoGRAMplusC4D 1000 Genomes-based GWAS
is a meta-analysis of GWAS of IHD case-control studies of
people of mainly European (77%), South Asian, and East Asian
descent imputed using the 1000 Genomes phase 1 v3 training
set with 38 million variants. The study interrogated 9.4 million
Clinical Perspective
What Is New?
• Using Mendelian randomization on very large populations,
we do not ﬁnd any evidence of a causal role of vascular
endothelial growth factor in ischemic heart disease.
• The roles of speciﬁc vascular endothelial growth factor
subtypes on ischemic heart disease require further inves-
tigation.
What Are the Clinical Implications?
• Our results suggest that therapeutic strategies targeting
vascular endothelial growth factor may not be of beneﬁt for
ischemic heart disease.
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variants and included 60 801 IHD cases and 123 504
controls.11 Case status was deﬁned by an inclusive coronary
artery disease diagnosis such as myocardial infarction, acute
coronary syndrome, chronic stable angina, or coronary steno-
sis >50%. These were ascertained in various ways, such as
medical records, clinical diagnosis, procedures that indicate
coronary artery disease, medications or symptoms that
indicate angina, or self-reports as described elsewhere.11
Statistical Analyses
Estimates of the effect of VEGF on IHD were obtained from
separate sample instrumental variable analyses.14 We calcu-
lated SNP-speciﬁc Wald estimates and obtained the variance
using the Feiller theorem.15 We used inverse variance
weighting with ﬁxed effects to combine the SNP-speciﬁc
estimates for uncorrelated SNPs (ie, with r2<0.05), which is a
common approach for separate sample instrumental variable
analyses using summary data from GWAS. From the analysis
we reported the odds ratio per log-transformed increase in
VEGF for IHD with a 95%CI. However, inverse variance




We conducted MR-Egger analysis, which will give an unbiased
estimate even if all instruments are invalid (eg, presence of
directional pleiotropy).16 However, MR-Egger only gives valid
estimate if the Instrument Strength Independent of Direct
Effect (InSIDE) assumption holds. Unfortunately, the assump-
tion cannot be tested empirically because it would be violated
if many genetic instruments inﬂuence the same unmeasured
confounder of an exposure outcome relation.16 MR-Egger may
also be susceptible to effect estimate dilution due to violation
of a no-measurement-error assumption for instrument on
exposure. To assess the degree of such dilution, we assessed
the heterogeneity of the relation of genetic instruments on
exposure (I2GX) and adjusted the MR-Egger estimate using the
simulation extrapolation (SIMEX) method if I2GX was less than
90%.17 Furthermore, a very low I2GX would suggest that MR-
Egger may be less robust but nevertheless serve as an
indicator for the validity of this test.17 From the MR-Egger
regression, we also reported the intercept and the P value,
which indicate the presence of overall directional pleiotropy if
P value is <0.05.
Exclusion of Horizontal Pleiotropic SNPs/Lead SNP
We repeated the analyses, ie, inverse variance weighting and
MR-Egger with the exclusion of SNPs exhibiting horizontal
pleiotropy or the lead SNP, contributing more than 50% weight
in the overall analysis, as additional sensitivity analyses to
examine their impact on the overall estimate.
Power Calculation
We used the online calculator for power calculation of MR
studies (http://cnsgenomics.com/shiny/mRnd/) to estimate
power.18 In the original GWAS the variance explained by all 10
SNPs ranged from 19% to 52%.10 However, one of the SNPs
(rs34528081) was excluded because it was not genotyped in
CARDIoGRAMplusC4D 1000 Genomes and had no proxy.
Assuming the remaining 9 SNPs explained only the lower
bound of the total variance (ie, 19%), the sample size allows
estimation of an effect size of odds ratio 0.97 for IHD per
standard deviation of VEGF at 80% power with 5%
signiﬁcance.
All statistical analyses were conducted using R version
3.2.3 (R Foundation for Statistical Computing, Vienna, Austria)
using the package “TwoSampleMR” from Github19 and scripts
in the cited reference.17 The relevant scripts can be found in
Data S1.
This analysis of publicly available data does not require
ethical approval.
Results
Based on the most recent GWAS of VEGF, 10 SNPs reached
genome-wide signiﬁcance: rs1740073 (C6orf223), rs2375981
(KCNV2), rs2639990 (ZADH2), rs4782371 (ZFPM1),
rs6921438 (LOC100132354), rs7043199 (VLDLR-AS1),
rs10761741 (JMJD1C), rs6993770 (ZFPM2), rs114694170
(MEF2C), and rs34528081 (VEGFA), which explained up to
52% of the VEGF phenotypic variance.10 Among them,
rs34528081 (VEGFA) was not genotyped in the CARDIo-
GRAMplusC4D 1000 Genomes–based GWAS, and no proxy
for rs34528081 could be identiﬁed; hence, it could not be
included in the analyses. The remaining 9 SNPs were largely
uncorrelated, although rs1740073 was minimally correlated
with rs6921438 (r2<0.001) and rs2375981 with rs7043199
(r2=0.001), so all 9 SNPs were used. The SNP rs6993770
(ZFPM2) was potentially pleiotropic because it is associated
with platelets according to Ensembl (P=491017) and so
might affect IHD other than via VEGF. The lead SNP
(rs6921438 in LOC100132354) contributed 82% of the weight
in the inverse variance-weighting analysis. Information
extracted concerning these SNPs is given in Table S1.
Table shows the MR estimates for VEGF on IHD using
different methodological approaches. The inverse variance-
weighted estimate showed no clear association of VEGF with
IHD (odds ratio 0.99 per log-transformed pg/mL, 95%CI 0.96-
1.02) using all 9 SNPs. Figure 1 shows that rs6921438
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(LOC100132354) was most inﬂuential in the analysis. How-
ever, the estimate was not substantially different when
rs6921438 (LOC100132354) or rs6993770 (ZFPM2) or both
SNPs were excluded. The MR-Egger estimate gave an inverse
association of VEGF with IHD (odds ratio 0.95, 95%CI 0.91-
0.99) based on 9 SNPs or with rs6993770 (ZFPM2) excluded,
but the MR-Egger estimate was null after exclusion of
rs6921438 (LOC100132354) or both SNPs. The MR-Egger
intercept P value (P=0.02 using all 9 SNPs) suggested
directional pleiotropy, which is also reﬂected in the scatter-
plot of the genetic association of outcome against genetic
association of exposure for each genetic instrument included
in this study (Figure 2). However, this was no longer evident
after excluding rs6993770 (ZFPM2) (P=0.09), excluding
rs6921438 (LOC100132354) (P=0.78), or excluding both
rs6993770 (ZFPM2) and rs6921438 (LOC100132354)
(P=0.63). I2GX was >90% in all analyses, suggesting that
dilution of the MR-Egger estimate due to violation of the no-
measurement-error assumption was limited.
Discussion
This ﬁrst MR study examining the relation of VEGF with IHD
found little evidence for a causal role of VEGF in IHD,
consistent with meta-analysis of candidate gene studies.9
Therefore, the positive relation of VEGF with CVD seen in
observational studies is unlikely to be causal.3
The function of VEGF is diverse, ranging from angiogenesis,
vascular permeability, and tumorigenesis to possibly
atherosclerosis,6,20 which in turn has led to the development
of corresponding therapies for several diseases, including
cancer, CVD, and the retinopathy of prematurity.21 Although
VEGF-targeted therapies have had beneﬁts in cancer and
macular degeneration, albeit causing some side effects
including hypertension and ocular inﬂammation,20,22-25 bene-
ﬁts are less apparent in the treatment of ischemia.6 The
Framingham Heart Study suggested an inverted U-shaped
relation of VEGF with CVD, which could reﬂect a complex
action of VEGF on CVD or could be an artifact of confounding
and reverse causation.3 Other smaller studies also showed
conﬂicting results, where people with CVD did not always have
higher VEGF.26,27 Given the largely null ﬁndings from our study,
VEGF could possibly be a biomarker or symptom of CVD rather
than a cause. Similarly, randomized controlled trials did not
show that VEGF improved clinical outcomes, although the
effects were studied primarily in ischemic patients,6 as is
typical of smaller clinical trials. Nevertheless, better under-
standing of VEGF, such as its role in angiogenesis, and how the
drugs should be designed to bring about its intended effects,
may help to explain the null results in previous trials.28
Statins decrease cardiovascular risk more than would be
expected from their effects on lipids, suggesting that statins
may have multiple effects in addition to lowering low-density
lipoprotein cholesterol.29 Although statins lower VEGF, our
study suggests the additional beneﬁts of statins in reducing
CVD risk do not appear to be primarily due to statin inﬂuence
on VEGF although this is speculative and could only be
conﬁrmed in other study designs such as a mechanistic
randomized controlled trial.5 Previous studies primarily
focused on the effects of VEGF-A although other classes of
VEGF may have unknown effects relevant to CVDs.1 For
example, VEGF-B may have cytoprotective properties, and
animal studies have provided some evidence of clinical utility
such as delayed dilated cardiomyopathy progression, whereas
VEGF-C might be higher in those with ischemic cardiomyopa-
thy.1 Further investigation of the cardiovascular effects of
VEGF sub-types may provide additional insight into their
etiologic role in CVDs with corresponding implications for
drug development.30
The most inﬂuential SNP in this MR study of VEGF on IHD
is rs6921438 (LOC100132354), which is located downstream
of VEGF and close to C6orf23 but encodes a currently
uncharacterized protein,31 so it is difﬁcult to know why it is
relevant; rs6921438 might also be related to lipids, although
the P values did not reach genome-wide signiﬁcance
(1.29107 for high-density lipoprotein cholesterol and
Table. Estimates of the Effect of Genetically Predicted VEGF (per Log-Transformed pg/mL)10 on IHD11 Obtained From Mendelian
Randomization Using Different Methodological Approaches and Exclusions for Pleiotropic SNPs
Inverse Variance Weighting With
Fixed Effects MR-Egger
Odds Ratio 95%CI Odds Ratio 95%CI Intercept (P Value) I2GX
All 9 SNPs 0.99 0.96 to 1.02 0.95 0.91 to 0.99 0.016 (0.02) 99.8%
Excluding rs6993770 (ie, 8 SNPs) 0.98 0.96 to 1.01 0.95 0.92 to 0.99 0.012 (0.09) 99.8%
Excluding rs6921438 (ie, 8 SNPs) 1.08 1.02 to 1.15 1.06 0.90 to 1.24 0.003 (0.78) 97.1%
Excluding rs6993770 and rs6921438 (ie, 7 SNPs) 1.05 0.98 to 1.13 1.01 0.85 to 1.20 0.006 (0.63) 96.9%
IHD indicates ischemic heart disease; MR, Mendelian randomization; SNP, single nucleotide polymorphism; VEGF, vascular endothelial growth factor.
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1.59104 for low-density lipoprotein cholesterol).32 Some of
the gene regions including the other VEGF-related SNPs are
associated with other phenotypes.10,31 JMJD1C is related to
liver function, platelet counts, sex-hormone-binding globulin,
and androgen levels.10 ZFPM1 may be related to heart and
coronary vessel development. MEFC2 is related to neurode-
velopment.10 Because the SNPs used to predict VEGF lack
deﬁnitive characterization of their full functional effects, we
used MR-Egger regression and exclusion of potentially
pleiotropic SNPs to reduce the likelihood of bias as sensitivity
analyses.8 We found the inverse association of VEGF with IHD
that was no longer evident using MR-Egger regression
excluding rs6921438 (LOC100132354). The rs6921438 is
very inﬂuential (Figure 1) and may have been driving any
inverse association. Whether the potential inverse association
of VEGF with IHD is meaningful awaits clariﬁcation of the
functional role, or otherwise, of rs6921438 and the other
SNPs predicting VEGF in IHD.
Although we used separate sample instrumental variable
analysis with genetic instruments, which is less susceptible
to residual confounding than observational studies, limita-
tions exist. First, MR has stringent assumptions. We chose
SNPs that strongly predicted VEGF in GWAS.10 Because
genetic variants are randomly allocated during conception,
the genetic variants are unlikely to be associated with
potential confounders. We also used several MR techniques
Figure 1. Single-nucleotide polymorphism (SNP)-speciﬁc and overall estimates for the effect of vascular
endothelial growth factor (VEGF) (per log-transformed pg/mL)10 on ischemic heart disease (IHD)11 using
Mendelian randomization with inverse variance weighting with ﬁxed effects.
Figure 2. Scatterplot of the genetic association of outcome against genetic
association of VEGF for each single-nucleotide polymorphism used in this study10 on
ischemic heart disease (IHD).11 VEGF indicates vascular endothelial growth factor.
DOI: 10.1161/JAHA.117.005619 Journal of the American Heart Association 5






















including using MR-Egger regression, although we did not use
a weighted median because 82% of the weight came from the
lead SNP for VEGF (rs6921438 in LOC100132354) when a
weighted median estimate gives consistent estimates only if
more than 50% of the weight is from valid instruments.14 We
also repeated the analyses excluding rs6921438
(LOC100132354) to check if the estimates were driven by
this lead SNP. We searched comprehensively from genotype
to phenotype to identify potentially pleiotropic effects and
excluded potentially horizontal pleiotropic SNPs to reduce the
likelihood of biases due to violation of the instrumental
variable analysis. However, we are limited by current
knowledge and lack of access to summary statistics of all
genome-wide association studies of cardiovascular risk
factors to check for potential genetic associations, so we
cannot exclude the possibility that our estimates are biased
by currently unknown pleiotropic effects. Nevertheless, we
conducted MR-Egger regression, which is more robust to the
inclusion of invalid SNPs, and generally found no evidence for
the relation of VEGF and IHD risk, with estimates close to
null. Furthermore, we were unable to examine potential
nonlinearity of VEGF on IHD because we only used summary
statistics in this study, whereas the existing method for
assessing nonlinearity in MR requires individual-level data.33
Nevertheless, this could be further explored in the UK
Biobank once it accumulates enough IHD cases.34 Genomic
control in the GWAS reduced the likelihood of confounding by
population stratiﬁcation.10,11 The SNPs included in this study
were replicated, and we used estimates from the discovery
and replication stages combined. Hence, the results should
be less susceptible to the winner’s curse. However, a small
proportion (5%) of the 184 305 participants in CARDIo-
GRAMplusC4D1000 Genomes–based GWAS come from the
VEGF GWAS (n=9548), and any resulting bias due to winner’s
curse could underestimate the association between VEGF
and IHD risk.35 Channeling bias is also unlikely because the
genetic variants were randomly allocated at conception and
hence should not be determined by other factors. Second, we
assumed the genetic association with VEGF was present in
CARDIoGRAMplusC4D 1000 Genomes–based GWAS, which
is likely, as both studies mainly included adults of European
descent.10,11 Third, we did not apply the VEGF SNPs to
CARDIoGRAMplusC4D metabochip, as it only had 3 VEGF
SNPs (rs6921438, rs6993770, and rs10761741).36-38 Based
on these 3 VEGF-related SNPs, the association of VEGF with
IHD was 1.00 (95%CI 0.96-1.05) using inverse variance
weighting with ﬁxed effects, and the MR-Egger regression
estimate was 0.96 (95%CI 0.62-1.48) similar to the analyses
using CARDIoGRAMplusC4D 1000 Genomes–based GWAS,
although the MR-Egger regression estimates had a wider
conﬁdence interval. Nevertheless, differences in sample size
and population characteristics between the 2 CARDIoGRAM
GWAS might have contributed to any differences. Fourth, we
were unable to include rs34528081 (VEGFA) in the analyses
because it was not genotyped in the CARDIoGRAMplusC4D
1000 Genomes–based GWAS, and no proxy SNPs could be
identiﬁed for it. VEGFA is the main genetic locus-determining
serum VEGF,39 so we cannot rule out the possibility that
inclusion of this SNP could produce a different estimate for
the effect of VEGF on IHD or that VEGF-A may have a
different effect from other types of VEGF. Nevertheless, we
have also included other SNPs, which may have better
predictive power than VEGFA, based on the estimates for
these SNPs on VEGF compared to the estimates for
rs34528081 (VEGFA) on VEGF.10 Fifth, our study does not
provide direct evidence on the role of VEGF in ischemia
treatment, given that participants included in this study are
not only patients suffering from ischemia. However, causal
effects are usually consistent.
This MR study suggests that the observed positive
association of VEGF with IHD is unlikely to be causal. Further
MR studies using individual-level data may be useful to
delineate any potential nonlinearity between VEGF and IHD
risk and to identify the effects across classes of VEGF.
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Scripts for the analysis 
 
#R script for the paper (JAHA, 2017) 
## Inverse variance weighting with fixed effect 




#Create dataframe for analysis (Post allele harmonization)  
snp <- c("rs1740073", "rs2375981", "rs2639990", "rs4782371", "rs6921438", "rs6993770", "rs7043199", 
"rs10761741", "rs114694170") 
bx <- c(0.09,0.21,0.11,0.07,0.64,0.16,0.1,0.08,0.15) 
bxse <- c(0.01,0.01,0.018,0.011,0.008,0.01,0.013,0.009,0.023) 
by <- c(0.012844,0.008435,0.013316,0.005059,-0.019603,0.027433,-0.005214,0.006922,0.001106) 
byse <- c(0.0109920,0.0096472,0.0212769,0.0112289,0.0094876,0.0101545,0.0142791,0.0092442,0.0254852) 
 
VEGF  <- data.frame(snp, bx, bxse, by, byse) 
 
#All SNPs 
# Calculating IV estimates manually using Feiller's theorem 
VEGF$IV_estimate<-by/bx 
VEGF$IV_SE <- sqrt(((by/bx)^2)*((byse^2/(by^2))+(bxse^2/(bx^2)))) 
 
results<-metagen(VEGF$IV_estimate, VEGF$IV_SE, sm="OR", VEGF$snp) 








results<-metagen(VEGF_2$IV_estimate, VEGF_2$IV_SE, sm="OR", studlab=VEGF_2$snp) 
 
#Excluding rs6993770 and rs6921438 
VEGF_3<-subset(VEGF, snp!="rs6993770"&snp!="rs6921438") 
results<-metagen(VEGF_3$IV_estimate, VEGF_3$IV_SE, sm="OR", studlab=VEGF_3$snp) 
 
#Scatterplot 
plot(VEGF$bx, VEGF$by, xlab="Genetic association with VEGF", ylab="Genetic association with IHD") 
abline(lm(VEGF$by~VEGF$bx, weights = VEGF$byse^-2)) 
 
####MR-Egger 


















#Create dataframe for analysis (Post harmonization)  
#Exposure Dataframe  
SNP <- c("rs1740073", "rs2375981", "rs2639990", "rs4782371", "rs6921438", "rs6993770", "rs7043199", 
"rs10761741", "rs114694170") 
beta <- c(0.09,0.21,0.11,0.07,0.64,0.16,0.1,0.08,0.15) 
se <- c(0.01,0.01,0.018,0.011,0.008,0.01,0.013,0.009,0.023) 
effect_allele <-c("T","C","T","G","G","A","T","T","C") 
 
VEGF <- data.frame(SNP, beta, se, effect_allele) 
Exp_data <- format_data(VEGF, type="exposure") 
 
#Outcome Dataframe  
SNP <- c("rs1740073", "rs2375981", "rs2639990", "rs4782371", "rs6921438", "rs6993770", "rs7043199", 
"rs10761741", "rs114694170") 
beta <- c(0.012844,0.008435,0.013316,0.005059,-0.019603,0.027433,-0.005214,0.006922,0.001106) 
se <- c(0.0109920,0.0096472,0.0212769,0.0112289,0.0094876,0.0101545,0.0142791,0.0092442,0.0254852) 
effect_allele <-c("T","C","T","G","G","A","T","T","C") 
 
IHD <- data.frame(SNP, beta, se, effect_allele) 
Out_data <- format_data(IHD, type="outcome") 
 
dat <- harmonise_data( 
  exposure_dat = Exp_data, 
  outcome_dat = Out_data,  






res$OR <- exp(res$b) 
res$LCI <- exp(res$b-1.96*res$se) 
res$UCI <- exp(res$b+1.96*res$se) 
res  
 
egg.int<-mr_pleiotropy_test(dat) #Test for directional pleiotropy (MR-Egger)  
 
#I2 
Isq = function(y,s){ 
  k = length(y) 
  w = 1/s^2; sum.w = sum(w) 
  mu.hat = sum(y*w)/sum.w 
  Q = sum(w*(y-mu.hat)^2) 
  Isq = (Q - (k-1))/Q 
  Isq = max(0,Isq) 






dat_1 <- subset(dat, SNP!="rs6993770") 
res<-mr(dat_1) 
 
res$OR <- exp(res$b) 
res$LCI <- exp(res$b-1.96*res$se) 







res$UCI <- exp(res$b+1.96*res$se) 
res  
 







dat_2 <- subset(dat, SNP!="rs6921438") 
res<-mr(dat_2) 
 
res$OR <- exp(res$b) 
res$LCI <- exp(res$b-1.96*res$se) 
res$UCI <- exp(res$b+1.96*res$se) 
res  
 





#Excluding rs6993770 and rs6921438 
dat_3 <- subset(dat, SNP!="rs6921438"&SNP!="rs6993770") 
res<-mr(dat_3) 
 
res$OR <- exp(res$b) 
res$LCI <- exp(res$b-1.96*res$se) 
res$UCI <- exp(res$b+1.96*res$se) 
res  
 












Table S1. Characteristics of single nucleotide polymorphisms (SNPs) used in the Mendelian 
Randomization analysis of the effect of vascular endothelial growth factor (VEGF) (per log 
transformed pg/ml)1 on ischemic heart disease (IHD)2  
 
Genome wide association study  
on VEGF 
CARDIoGRAMplusC4D 1000 











per effect allele 
(SE)   
P value 
Increase in log odds 
per effect allele (SE) 
P value 
rs1740073 T/C 0.09 (0.01) 4.4x10-17 0.0128 (0.011) 0.24 
rs2375981 C/G 0.21 (0.01) 9.49x10-99 0.008 (0.0096) 0.38 
rs2639990 T/C 0.11 (0.018) 5.85x10-10 0.013 (0.021) 0.53 
rs4782371 G/T 0.07 (0.011) 1.26x10-9 0.005 (0.011) 0.65 
rs6921438 G/A 0.64 (0.008) 1.66x10-1449 -0.020 (0.009) 0.04 
rs6993770 A/T 0.16 (0.01) 3.83x10-55 0.027 (0.010) 0.007 
rs7043199 T/A 0.10 (0.013) 4.16x10-14 -0.005 (0.014) 0.72 
rs10761741 T/G 0.08 (0.009) 2.99x10-19 0.007 (0.009) 0.45 
rs114694170 C/T 0.15 (0.023) 1.09x10-11 0.001 (0.025) 0.97 
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